Table 2.
The clinical features of SCG compared to CG
| Characteristics | SCG (n = 179) | CG (n = 179) | P value |
|---|---|---|---|
| Age (Mean ± SD) | 52.55 ± 10.27 | 52.23 ± 10.34 | 0.774a |
| Gender (Male) | |||
| Female (n, %) | 71 (39.7) | 71 (39.7) | 1.000b |
| Male (n, %) | 108 (60.3) | 108 (60.3) | |
| CRF | |||
| Yes (n, %) | 81 (45.2) | 95 (53.1) | 0.139b |
| No (n, %) | 98 (54.8) | 84 (46.9) | |
| Blood Tests | |||
| RBC (×1012/L) | 4.12 ± 0.83 | 4.15 ± 0.71 | 0.671a |
| HGB (g/L) | 114.06 ± 16.39 | 118.37 ± 21.51 | 0.034a |
| PLT (×109/L) | 207.96 ± 61.05 | 195.27 ± 57.22 | 0.043a |
| MPV (fl) | 8.37 ± 1.77 | 8.29 ± 1.46 | 0.651a |
| TT (s) | 13.20 ± 1.86 | 12.99 ± 1.65 | 0.266a |
| PT (s) | 12.15 ± 1.47 | 12.09 ± 1.40 | 0.724a |
| APTT(s) | 31.73 ± 3,42 | 32.05 ± 3,46 | 0.378a |
| INR | 1.05 ± 0.14 | 1.04 ± 0.12 | 0.607a |
| FIB (g/l) | 4.62 ± 1.09 | 4.69 ± 1.16 | 0.527a |
| D dimmer (ng/mL) | 795.43 ± 287.92 | 413.43 ± 265.71 | < 0.001a |
| CA 125 (U/ml) | 570.23 ± 240.19 | 107.10 ± 70.07 | < 0.001a |
| CA 155 (U/ml) | 81.73 ± 43.09 | 89.80 ± 44.53 | 0.082a |
| CA 199 (U/ml) | 261.19 ± 186.08 | 83.65 ± 48.79 | < 0.001a |
| Type of therapy (n = 164) (n, %) | |||
| Chemoradiotherapy | 53 (32.3) | 101 (61.6) | < 0.001b |
| Surgery | 111 (67.7) | 63 (38.4) | |
| Cancer metastasis (n, %) | |||
| Yes | 86 (48.0) | 25 (14.0) | < 0.001b |
| No | 93 (52.0) | 154 (86.0) | |
| Prognosis at the 30th day from cerebral infarction onset | |||
| Survival (n, %) | 166 (92.7) | 174 (97.2) | 0.053b |
| Death (n, %) | 13 (7.3) | 5 (2.8) |
Compared to CG,
a
with two independent samples t-test;
b
with chi-square test.
CRF, Conventionalrisk factors; RBC, red blood cells; HGB, hemoglobin; PLT, platelet; MPV, mean platelet volume; TT, thrombin time; PT, pro-thrombin time; APTT, activated partial thromboplastin time; INR, international normalized ratio; FIB, fibrinogen; CA, cancer antigen; SD, standard deviation.